{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:36:50Z","timestamp":1781829410279,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cld.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T01:29:18Z","timestamp":1663118958000},"page":"629-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic Scoring Systems in Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"26","author":[{"given":"Miki","family":"Scaravaglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2022.06.005_bib1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.06.005_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fmed.2020.00117","article-title":"New therapeutic targets in autoimmune cholangiopathies","volume":"7","author":"Gerussi","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.cld.2022.06.005_bib3","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2022.06.005_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2013 2021 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.06.005_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hep.1840100102","article-title":"Prognosis in primary biliary cirrhosis: model for decision making","volume":"10","author":"Dickson","year":"1989","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.005_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198301063080101","article-title":"The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis","volume":"308","author":"Roll","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2022.06.005_bib7","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0016-5085(85)90213-6","article-title":"Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis","volume":"89","author":"Christensen","year":"1985","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.06.005_bib8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0016-5085(89)91698-3","article-title":"Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial","volume":"97","author":"Leuschner","year":"1989","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.06.005_bib9","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s00535-013-0903-1","article-title":"Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients","volume":"49","author":"Lammert","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cld.2022.06.005_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.005_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Par\u00e9s","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.06.005_bib12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.005_bib13","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.06.005_bib14","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2022.06.005_bib15","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.06.005_bib16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis: HEPATOLOGY, Vol. XX, NO. X, 2015","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.005_bib17","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.06.005_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2022.06.005_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2022.06.005_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2022.06.005_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2022.06.005_bib22","doi-asserted-by":"crossref","unstructured":"Carbone M, Harms MH, Lammers WJ, et\u00a0al. Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis. Hepatol Commun 2018; 2: 683\u2013692.","DOI":"10.1002\/hep4.1180"},{"key":"10.1016\/j.cld.2022.06.005_bib23","doi-asserted-by":"crossref","unstructured":"Honda A, Tanaka A, Kaneko T, et\u00a0al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology 2019; 70: 2035\u20132046.","DOI":"10.1002\/hep.30552"},{"key":"10.1016\/j.cld.2022.06.005_bib24","doi-asserted-by":"crossref","first-page":"E4155","DOI":"10.3390\/molecules24224155","article-title":"Synthesis of novel farnesoid X receptor agonists and validation of their efficacy in activating differentiation of mouse bone marrow-derived mesenchymal stem cells into osteoblasts","volume":"24","author":"Fujimori","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.cld.2022.06.005_bib25","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.06.005_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/S0618-8278(19)30002-7","article-title":"GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: interim efficacy results of a phase 2 clinical trial","volume":"70","author":"Dalekos","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.06.005_bib27","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S0168-8278(18)30426-4","article-title":"Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing phase 2 study","volume":"68","author":"Schramm","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.06.005_bib28","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/apt.13984","article-title":"Editorial: scoring systems in primary biliary cholangitis - time to make a move","volume":"45","author":"Mells","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2022.06.005_bib29","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2022.06.005_bib30","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2022.06.005_bib31","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D\u2019Amato","year":"2021","journal-title":"JHEPReport"},{"key":"10.1016\/j.cld.2022.06.005_bib32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2022.06.005_bib33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2022.06.005_bib34","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.22517","article-title":"Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay","volume":"48","author":"Mayo","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.005_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.25599","article-title":"Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis","volume":"56","author":"Corpechot","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.005_bib36","doi-asserted-by":"crossref","unstructured":"Cristoferi L, Calvaruso V, Overi D, et\u00a0al. Accuracy of transient elastography in assessing fibrosis at diagnosis in na\u00efve patients with primary biliary cholangitis: a dual cut-off approach. Hepatology 2021; 74: 1496\u20131508.","DOI":"10.1002\/hep.31810"},{"key":"10.1016\/j.cld.2022.06.005_bib37","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nrg.2018.4","article-title":"Integrative omics for health and disease","volume":"19","author":"Karczewski","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.cld.2022.06.005_bib38","first-page":"15141","article-title":"Machine learning in primary biliary cholangitis: a novel approach for risk stratification","volume":"liv","author":"Gerussi","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2022.06.005_bib39","doi-asserted-by":"crossref","first-page":"104292","DOI":"10.1016\/j.ejmg.2021.104292","article-title":"The genetic architecture of primary biliary cholangitis","volume":"64","author":"Gerussi","year":"2021","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.cld.2022.06.005_bib40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jhep.2021.04.055","article-title":"An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs","volume":"75","author":"Cordell","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2022.06.005_bib41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/ng.789","article-title":"The Wellcome Trust Case Control Consortium 3, Mells GF, et\u00a0al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis","volume":"43","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.cld.2022.06.005_bib42","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/ajt.12132","article-title":"Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation","volume":"13","author":"Carbone","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2022.06.005_bib43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.cld.2022.06.005_bib44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-019-0127-1","article-title":"Benefits and limitations of genome-wide association studies","volume":"20","author":"Tam","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.cld.2022.06.005_bib45","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ebiom.2016.11.021","article-title":"Early molecular stratification of high-risk primary biliary cholangitis","volume":"14","author":"Hardie","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.cld.2022.06.005_bib46","doi-asserted-by":"crossref","first-page":"e0184292","DOI":"10.1371\/journal.pone.0184292","article-title":"MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2022.06.005_bib47","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1002\/hep.32011","article-title":"The serum proteome and ursodeoxycholic acid response in primary biliary cholangitis","volume":"74","author":"Barron-Millar","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2022.06.005_bib48","doi-asserted-by":"crossref","first-page":"803098","DOI":"10.3389\/fmolb.2021.803098","article-title":"Biliary Epithelial senescence in liver disease: there will Be SASP","volume":"8","author":"Meadows","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.cld.2022.06.005_bib49","doi-asserted-by":"crossref","first-page":"21813","DOI":"10.1073\/pnas.2001429117","article-title":"Multiomic blood correlates of genetic risk identify presymptomatic disease alterations","volume":"117","author":"Wainberg","year":"2020","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.cld.2022.06.005_bib50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-020-2715-9","article-title":"LifeTime and improving European healthcare through cell-based interceptive medicine","volume":"587","author":"Rajewsky","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cld.2022.06.005_bib51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaut.2018.10.024","article-title":"Prognostic models in primary biliary cholangitis","volume":"95","author":"Cristoferi","year":"2018","journal-title":"J\u00a0Autoimmun"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326122000435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:00:03Z","timestamp":1761069603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326122000435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1089326122000435"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.005","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Scoring Systems in Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}